Sarah K Keedy1, James L Reilly2, Jeffrey R Bishop3, Peter J Weiden4, John A Sweeney5. 1. Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL; skeedy@uchicago.edu. 2. Department of Psychiatry, Northwestern University, Chicago, IL; 3. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL; 4. Department of Psychiatry, University of Illinois at Chicago, Chicago, IL; 5. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
BACKGROUND: Antipsychotic medications have established clinical benefit, but there are few neuroimaging studies before and after initiating antipsychotic medication to assess drug influence on brain circuitry. Attention and motor learning tasks are promising approaches for examining treatment-related changes in frontostriatal systems. METHODS: Twenty-one unmedicated first-episode schizophrenia patients (14 antipsychotic-naïve) participated in functional imaging studies while performing visual attention (prosaccades) and motor learning tasks (predictive saccades). Posttreatment testing was completed in 14 patients after 4-6 weeks of antipsychotic treatment. Matched healthy controls were studied in parallel. RESULTS: Pretreatment, patients had reduced activation in the dorsal neocortical visual attention network. Activation deficits were significantly reduced posttreatment. Higher medication dose was associated with greater caudate activation at follow-up. For the motor learning task, patients' dorsolateral prefrontal cortex (DLPFC) was unimpaired prior to treatment but showed significantly reduced activation after treatment. CONCLUSION: Impairments in dorsal cortical attention networks are present in untreated first-episode schizophrenia patients. These impairments are reduced after antipsychotic treatment, suggesting a beneficial effect on neural systems for attention. Treatment-emergent decreases in DLPFC activation observed for the motor learning task are consistent with other clinical and preclinical evidence suggesting that antipsychotics can have adverse effects on prefrontal function.
BACKGROUND: Antipsychotic medications have established clinical benefit, but there are few neuroimaging studies before and after initiating antipsychotic medication to assess drug influence on brain circuitry. Attention and motor learning tasks are promising approaches for examining treatment-related changes in frontostriatal systems. METHODS: Twenty-one unmedicated first-episode schizophreniapatients (14 antipsychotic-naïve) participated in functional imaging studies while performing visual attention (prosaccades) and motor learning tasks (predictive saccades). Posttreatment testing was completed in 14 patients after 4-6 weeks of antipsychotic treatment. Matched healthy controls were studied in parallel. RESULTS: Pretreatment, patients had reduced activation in the dorsal neocortical visual attention network. Activation deficits were significantly reduced posttreatment. Higher medication dose was associated with greater caudate activation at follow-up. For the motor learning task, patients' dorsolateral prefrontal cortex (DLPFC) was unimpaired prior to treatment but showed significantly reduced activation after treatment. CONCLUSION: Impairments in dorsal cortical attention networks are present in untreated first-episode schizophreniapatients. These impairments are reduced after antipsychotic treatment, suggesting a beneficial effect on neural systems for attention. Treatment-emergent decreases in DLPFC activation observed for the motor learning task are consistent with other clinical and preclinical evidence suggesting that antipsychotics can have adverse effects on prefrontal function.
Authors: Su Lui; Tao Li; Wei Deng; Lijun Jiang; Qizhu Wu; Hehan Tang; Qiang Yue; Xiaoqi Huang; Raymond C Chan; David A Collier; Shashwath A Meda; Godfrey Pearlson; Andrea Mechelli; John A Sweeney; Qiyong Gong Journal: Arch Gen Psychiatry Date: 2010-08
Authors: Meina Quan; Sang-Hyuk Lee; Marek Kubicki; Zora Kikinis; Yogesh Rathi; Larry J Seidman; Raquelle I Mesholam-Gately; Jill M Goldstein; Robert W McCarley; Martha E Shenton; James J Levitt Journal: Schizophr Res Date: 2013-02-13 Impact factor: 4.939
Authors: Rebekka Lencer; Sarah K Keedy; James L Reilly; Bruce E McDonough; Margret S H Harris; Andreas Sprenger; John A Sweeney Journal: Psychiatry Res Date: 2011-08-27 Impact factor: 3.222
Authors: Jennifer E McDowell; Gregory G Brown; Martin Paulus; Antigona Martinez; Sara E Stewart; David J Dubowitz; David L Braff Journal: Biol Psychiatry Date: 2002-02-01 Impact factor: 13.382
Authors: Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams Journal: Psychopharmacology (Berl) Date: 2004-04-30 Impact factor: 4.530
Authors: Patricia Westmoreland Corson; Daniel S O'Leary; Del D Miller; Nancy C Andreasen Journal: Biol Psychiatry Date: 2002-11-01 Impact factor: 13.382
Authors: Sarah K Keedy; Jeffrey R Bishop; Peter J Weiden; John A Sweeney; Cherise Rosen; Robert Marvin; James L Reilly Journal: Schizophr Res Date: 2014-08-08 Impact factor: 4.939
Authors: Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen Journal: Eur J Clin Pharmacol Date: 2016-07-04 Impact factor: 2.953
Authors: Seenae Eum; S Kristian Hill; Ney Alliey-Rodriguez; James M Stevenson; Leah H Rubin; Adam M Lee; Lauren J Mills; James L Reilly; Rebekka Lencer; Sarah K Keedy; Elena Ivleva; Richard S E Keefe; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop Journal: Neuropsychopharmacology Date: 2021-06-18 Impact factor: 8.294
Authors: Henrik Nørbak-Emig; Bjørn H Ebdrup; Birgitte Fagerlund; Claus Svarer; Hans Rasmussen; Lars Friberg; Peter N Allerup; Egill Rostrup; Lars H Pinborg; Birte Y Glenthøj Journal: Int J Neuropsychopharmacol Date: 2016-04-29 Impact factor: 5.176
Authors: Nina Vanessa Kraguljac; David Matthew White; Jennifer Ann Hadley; Kristina Visscher; David Knight; Lawrence ver Hoef; Blessing Falola; Adrienne Carol Lahti Journal: Neuroimage Clin Date: 2015-11-22 Impact factor: 4.881